Mabion is a Champion of the 2025 International CDMO Leadership Award in Biologics
- Mabion has been recognized as the Champion of the 2025 International CDMO Leadership for Biologics.
- Mabion emerged as a leader in the Biologics – International category, demonstrating its commitment to high standards and customer satisfaction.
We are thrilled to announce that Mabion has been named the Champion of the 2025 International CDMO Leadership Award in Biologics. This prestigious honor reinforces Mabion’s position as a leading International CDMO for Biologics, delivering world class development and manufacturing services to pharma and biotech companies.
This award is a reflection of the trust and confidence our partners place in us. We are deeply grateful to our clients for their continued collaboration and valuable feedback. Their support fuels our passion for innovation and motivates us to push the boundaries of biologics development and manufacturing.
The award was personally received by Adam Pietruszkiewicz, Mabion’s Chief Commercial Officer, during DCAT Week in New York City. This global event brings together key decision-makers in the pharmaceutical industry, providing an excellent platform to celebrate this achievement and engage with partners.
The CDMO Leadership Awards, organized by Life Science Connect, Outsourced Pharma and Orientation Marketing, recognize top-performing CDMOs based on direct client feedback. More than 210 CDMOs were evaluated on critical factors, including quality, expertise, service, and reliability. Mabion stood out in the Biologics – International category, demonstrating its commitment to excellence and client satisfaction.
Being named Champion in this category underscores our unwavering commitment to excellence, reliability, and scientific innovation. It is a testament to the trust our partners place in us and our relentless pursuit of delivering high-quality CDMO solutions that help bring breakthrough biologics to market.
We also extend our congratulations to all the other winners and finalists who continue to shape the future of the CDMO industry.
For more information about Mabion’s capabilities as an International CDMO for Biologics, check out our Services.
Prepared by:
